Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Short Interest Update

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 27,527,415 shares, a drop of 15.2% from the February 12th total of 32,453,225 shares. Based on an average daily volume of 3,871,657 shares, the days-to-cover ratio is currently 7.1 days. Approximately 30.4% of the shares of the company are sold short. Approximately 30.4% of the shares of the company are sold short. Based on an average daily volume of 3,871,657 shares, the days-to-cover ratio is currently 7.1 days.

Acadia Healthcare Trading Down 2.6%

Shares of ACHC stock opened at $23.52 on Monday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.55 and a current ratio of 1.55. Acadia Healthcare has a fifty-two week low of $11.43 and a fifty-two week high of $31.04. The company has a market cap of $2.17 billion, a PE ratio of -1.93, a P/E/G ratio of 7.95 and a beta of 0.73. The stock’s fifty day moving average price is $16.80 and its two-hundred day moving average price is $18.73.

Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. Acadia Healthcare had a positive return on equity of 6.53% and a negative net margin of 33.29%.The business had revenue of $821.46 million during the quarter, compared to the consensus estimate of $800.10 million. During the same period in the prior year, the company earned $0.64 EPS. Acadia Healthcare’s revenue for the quarter was up 6.1% on a year-over-year basis. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. Equities analysts predict that Acadia Healthcare will post 3.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ACHC. UBS Group boosted their price target on Acadia Healthcare from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Zacks Research raised Acadia Healthcare from a “strong sell” rating to a “hold” rating in a report on Thursday, March 5th. Raymond James Financial reiterated an “outperform” rating and set a $25.00 target price on shares of Acadia Healthcare in a research report on Thursday, February 26th. Deutsche Bank Aktiengesellschaft decreased their price target on Acadia Healthcare from $33.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, December 3rd. Finally, Bank of America cut shares of Acadia Healthcare from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $21.50 to $13.00 in a research report on Wednesday, December 3rd. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Acadia Healthcare has an average rating of “Hold” and a consensus price target of $21.15.

Institutional Investors Weigh In On Acadia Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allworth Financial LP increased its position in Acadia Healthcare by 676.4% during the 2nd quarter. Allworth Financial LP now owns 1,351 shares of the company’s stock worth $31,000 after purchasing an additional 1,177 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Acadia Healthcare by 54.8% in the second quarter. EverSource Wealth Advisors LLC now owns 1,404 shares of the company’s stock valued at $32,000 after buying an additional 497 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of Acadia Healthcare by 501.9% during the third quarter. Hantz Financial Services Inc. now owns 2,185 shares of the company’s stock worth $54,000 after buying an additional 1,822 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Acadia Healthcare by 208.9% during the fourth quarter. Wells Fargo & Company MN now owns 2,233 shares of the company’s stock worth $32,000 after buying an additional 1,510 shares in the last quarter. Finally, Quent Capital LLC bought a new position in shares of Acadia Healthcare in the 3rd quarter valued at $71,000.

More Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia added Daniel Cancelmi to its Board of Directors, a governance move that can be viewed positively as expanding board expertise and oversight. Article Title
• Neutral Sentiment: Reported short-interest data shows zero shares and days-to-cover of 0.0 — the release appears to contain anomalous or missing data (NaN/0) and therefore provides no clear signal about bearish positioning.
• Negative Sentiment: Zacks Research cut multiple near-term and multi-year EPS estimates and keeps a “Hold” rating. Key changes include Q2 2026 EPS cut to $0.49 (from $0.66), FY2026 to $1.48 (from $1.85), and FY2027 to $1.55 (from $1.96), plus several quarter-by-quarter reductions across 2026–2027. These downward revisions lower investor expectations and are the main reason for today’s downward pressure on the stock.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.